EcoDrugPlus

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSPTXG00000010343
Gene Symbol: RELA
1 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPTXG00000007063
Gene Symbol: RAF1
3 Cross references
221 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSPTXG00000005691
Gene Symbol: ROCK1
1 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSPTXG00000012863
Gene Symbol: ROCK2
1 Cross references
303 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sem1 26s Proteasome Subunit

Ensembl ID : ENSPTXG00000013617
Gene Symbol: SEM1
1 Cross references
155 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPTXG00000007524
Gene Symbol: SRC
3 Cross references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSPTXG00000014264
Gene Symbol: TEK
1 Cross references
163 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSPTXG00000016839
Gene Symbol: UGCG
3 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSPTXG00000017478
Gene Symbol: WEE1
3 Cross references
226 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSPTXG00000007034
Gene Symbol: YES1
3 Cross references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSPTXG00000012909
Gene Symbol: ACHE
3 Cross references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Activin A Receptor Type 2b

Ensembl ID : ENSPTXG00000018871
Gene Symbol: ACVR2B
3 Cross references
257 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).